These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 9522603)

  • 1. In search of a superaspirin for the heart.
    Verheugt FW
    Lancet; 1997 May; 349(9063):1409-10. PubMed ID: 9164311
    [No Abstract]   [Full Text] [Related]  

  • 2. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
    Klinkhardt U; Kirchmaier CM; Westrup D; Graff J; Mahnel R; Breddin HK; Harder S
    Clin Pharmacol Ther; 2000 Mar; 67(3):305-13. PubMed ID: 10741635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
    Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
    Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition and reversal of platelet aggregation by alphaIIbbeta3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban.
    Frojmovic M; Labarthe B; Legrand C
    Br J Haematol; 2005 Nov; 131(3):348-55. PubMed ID: 16225655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic dissolution of an intracoronary thrombus by prolonged intravenous platelet glycoprotein IIb/IIIa antagonism.
    Radke PW; Janssens U; Schwarz ER; vom Dahl J
    J Invasive Cardiol; 1999 Nov; 11(11):679-81. PubMed ID: 10745462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New antiplatelet agents].
    Diez-Ewald
    Invest Clin; 2000 Sep; 41(3):147-8. PubMed ID: 11029831
    [No Abstract]   [Full Text] [Related]  

  • 8. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring the right compound at the right time is not always easy.
    Brener SJ
    J Invasive Cardiol; 2010 Jan; 22(1):6-7. PubMed ID: 20048390
    [No Abstract]   [Full Text] [Related]  

  • 10. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
    Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
    Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction.
    Exaire JE; Fathi RB; Brener SJ; Karha J; Ellis SG; Bhatt DL
    Arch Cardiol Mex; 2006; 76(4):376-82. PubMed ID: 17315613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between level of platelet inhibition after early use of abciximab and myocardial reperfusion in ST-elevation acute myocardial Infarction treated by primary percutaneous coronary intervention.
    Pérez de Prado A; Fernández-Vázquez F; Cuellas JC; Alonso-Orcajo N; Carbonell R; Pascual C; Olalla C; Diego A; de Miguel A; Calabozo RG
    Am J Cardiol; 2006 Mar; 97(6):798-803. PubMed ID: 16516579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abciximab not RGD peptide inhibits von Willebrand factor-dependent platelet activation under shear.
    Goto S; Eto K; Ikeda Y; Handa S
    Lancet; 1999 Mar; 353(9155):809. PubMed ID: 10459966
    [No Abstract]   [Full Text] [Related]  

  • 14. Kistrin inhibits human smooth muscle cell interaction with fibrin.
    Yee KO; Ikari Y; Bodary S; Schwartz SM
    Thromb Res; 2000 Jan; 97(2):39-50. PubMed ID: 10688333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversies with On-TIME 2.
    Lin GM; Li YH; Chu KM; Han CL
    Heart; 2011 Jun; 97(12):1026; author reply 1026. PubMed ID: 21586427
    [No Abstract]   [Full Text] [Related]  

  • 16. TRIAD system catalase, insulin, and low dose aspirin neutralize the effect of dermcidin isoform-2 and prevent cell death in acute myocardial infarction and recurrence of the disease.
    Bank S; Maiti S; Guha S; Sinha AK
    Cardiol J; 2016; 23(6):623-625. PubMed ID: 27976793
    [No Abstract]   [Full Text] [Related]  

  • 17. [Superaspirin in the platelet aggregation inhibitor therapy].
    Rossi G
    Recenti Prog Med; 1997 Dec; 88(12):590-1. PubMed ID: 9522603
    [No Abstract]   [Full Text] [Related]  

  • 18. [The value of Abciximab in stent implantation clearly proven].
    Z Kardiol; 1999 Jun; 88(6 Suppl):1-4. PubMed ID: 10434386
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.